Ashneer Grover said if news about PharmEasy seeking new funding is correct, "it's not a down round, it's the end". "Because anti-dilutive clause will kick in...Founders+ESOP holding will become 0.001% or some similar fraction! Debt taken in 2021 will...be most expensive capital raised by founders ever," Grover said. "Down round+anti-dilutive clause=Sudden death (jhatka) for founders," he added.